Biogen has reported two-year data from its Phase II CELIA trial showing that diranersen (BIIB080) slowed clinical decline in early Alzheimer’s disease patients.
The randomised, double-blind, placebo-controlled, dose-ranging trial (NCT05399888) evaluated intrathecally administered the tau-targetting therapy in 416 patients with mild cognitive impairment or mild dementia due to Alzheimer’s.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study enrolled patients who had not previously received anti-amyloid therapies to evaluate 60mg and 115mg of the drug every six months or 115mg every three months.
The primary endpoint measured dose response for changes from baseline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at week 76, alongside secondary clinical, biomarker, and imaging measures.
At week 96, during the ongoing open-label extension phase, the 60mg twice-yearly regimen demonstrated the largest treatment effects across measures of cognition, function, and disease progression.
In that cohort, CDR-SB decline slowed by 38% compared with placebo-equivalent controls, representing a 1.09-point difference, alongside a 54% effect on Alzheimer’s disease assessment scale–cognitive subscale (ADAS-Cog13).
Activities of daily living on ADCS-ADL-MCI showed a 30% slowing, while Alzheimer’s disease composite score (ADCOMS) and modified integrated Alzheimer’s disease rating scale (iADRS) showed 38% and 46% effects, respectively, alongside 38% on mini-mental state examination (MMSE).
Biogen reported clinical benefits across every dose tested, adding that diranersen maintained a generally well-tolerated profile over two years without generating new safety concerns.
The company presented the data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference.
Biogen executive vice-president and development head Priya Singhal said: “The two-year data presented at CTAD mark an important milestone for diranersen, demonstrating not only sustained clinical benefit but also an increasing magnitude of effect at two years.
“These findings strengthen the growing body of evidence supporting tau as a therapeutic target and underscore the potential of diranersen to meaningfully impact disease progression for people living with early Alzheimer’s disease.”
At 18 months, placebo-controlled data demonstrated targeted benefits in memory, orientation, and executive function, coupled with widespread decreases in cerebrospinal fluid (CSF) p-tau181, plasma p-tau217, and brain tau positron emission tomography (PET) signals.
Discovered by Ionis Pharmaceuticals, diranersen is an investigational antisense oligonucleotide therapy that was licensed worldwide to Biogen in 2019.
It acts on microtubule-associated protein tau messenger ribonucleic acid (MAPT mRNA) to curb both extracellular and intracellular tau formation.
Dr Richard Oakley, associate director for research and innovation at Alzheimer’s Society, said: “Diranersen is a particularly interesting therapy because it targets tau at its source. It works a bit like a gene ‘off-switch’, reducing the amount of tau the brain produces rather than trying to clear it once it has already built up. The treatment is given via lumbar puncture into the fluid around the spinal cord.
“The latest clinical trial results for this drug are very encouraging. They suggest that diranersen effectively reduces the buildup of tau in the brain, and the treatment’s ability to slow worsening of memory and thinking problems increases over two years.
“If these promising findings are confirmed in the upcoming phase three trial, a significant new treatment option for early Alzheimer’s disease could be within touching distance.”
